Chondroitin sulfate sodium
As of the edition of 20 October 2026, Chondroitin sulfate sodium is a drug: marketed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed
- Kind
- Unknown
- Brand name
- Atrofort Duo
- Approvals on record
- 11 in 11 regions
- Holder of the most recent approval
- Labialfarma - Laboratório De Produtos Farmacêuticos E Nutracêuticos, S.A.; 7 holders in all
- Registered trials
- 1, 1 stopped early
- Disease areas
- Bones, joints and muscles
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 3 | 1 | 0 | 0 | 1 |
| All trials | 1 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| IBSA Institut Biochimique | Lead sponsor of trials | 2023 to now |